Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production

Journal of Hypertension

Volumn 29, Issue 4, 2011, Pages 724-731

  Siddiquee, Khandaker ^a   Hampton, Jessica ^a   Khan, Susan ^b   Zadory, Dan ^b   Gleaves, Linda ^c   Vaughan, Douglas E ^c   Smith, Layton H ^a  

^a BURNHAM INSTITUTE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

angiotensin II; apelin; fibrosis; plasminogen activator inhibitor type 1

Indexed keywords

ANGIOTENSIN II; APELIN; APELIN 13; MESSENGER RNA; MYOSIN LIGHT CHAIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RHO KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; WILD TYPE;

EID: 79952745361     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834347de     Document Type: Article

References (38)

1. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251:471-476. (Pubitemid 28505047)
2. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136. (1-2):355-360. (Pubitemid 24049270)
3. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept 2005; 126:233-240. (Pubitemid 40128188)
4. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999; 1452:25-35. (Pubitemid 29486739)
5. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001; 1538 (2-3):162-171. (Pubitemid 32402239)
6. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 2001; 77:1085-1096. (Pubitemid 32467063)
7. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001; 99 (2-3):87-92. (Pubitemid 32522535)
8. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005; 65:73-82. (Pubitemid 40038480)
9. Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner T J, Woo YJ. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110 (11 Suppl 1):II187-II193. (Pubitemid 39263721)
10. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91:434-440. (Pubitemid 35034212)
11. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004; 279:26274-26279. (Pubitemid 38798776)
12. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118:3343-3354.
13. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
14. Griendling KK, Tsuda T, Berk BC, Alexander RW. Angiotensin II stimulation of vascular smooth muscle cells. Secondary signalling mechanisms. Am J Hypertens 1989; 2:659-665. (Pubitemid 19202876)
15. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93:2431-2437. (Pubitemid 24177156)
16. Kupfahl C, Pink D, Friedrich K, Zurbrugg HR, Neuss M, Warnecke C, et al. Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart. Cardiovasc Res 2000; 46:463-475. (Pubitemid 30319332)
17. Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993; 73:413-423. (Pubitemid 23238726)
18. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 2002; 109:787-796. (Pubitemid 34263155)
19. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type 1 and tissuetype plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90:362-368. (Pubitemid 24203700)
20. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest 1995; 95:1353-1362.
21. Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 2004; 164:449-456. (Pubitemid 38364661)
22. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95:995-1001.
23. Alexander CM, Werb Z. Proteinases and extracellular matrix remodeling. Curr Opin Cell Biol 1989; 1:974-982. (Pubitemid 20044899)
24. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005; 146:231-236. (Pubitemid 40051744)
25. Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL, et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107:132-134. (Pubitemid 43053534)
26. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008; 21:1288-1291.
27. Krajewska M, Smith LH, Rong J, Huang X, Hyer ML, Zeps N, et al. Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. J Histochem Cytochem 2009; 57:649-663.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408. (Pubitemid 34164012)
29. Schoenhard JA, Smith LH, Painter CA, Eren M, Johnson CH, Vaughan DE. Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2. J Mol Cell Cardiol 2003; 35:473-481. (Pubitemid 36539453)
30. Brown NJ, Muldowney JA 3rd, Vaughan DE. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition. Hypertension 2006; 47:441-448. (Pubitemid 43740288)
31. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18:1771-1779. (Pubitemid 28521068)
32. Li WW, Niu WQ, Zhang Y, Wu S, Gao PJ, Zhu DL. Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens 2009; 27:1194-1201.
33. Sukumaran V, Watanabe K, Veeraveedu PT, Thandavarayan RA, Gurusamy N, Ma M, et al. Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy. Hypertens Res 2010; 33:695-702.
34. Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, et al. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arterioscler Thromb Vasc Biol 2005; 25:365-371. (Pubitemid 40189159)
35. Matsui Y, Jia N, Okamoto H, Kon S, Onozuka H, Akino M, et al. Role of osteopontin in cardiac fibrosis and remodeling in angiotensin II-induced cardiac hypertrophy. Hypertension 2004; 43:1195-1201. (Pubitemid 38691740)
36. Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG. Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 2007; 74:388-395. (Pubitemid 46693698)
37. Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, et al. Apelin activates Larginine/ nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 2007; 28:2023-2029. (Pubitemid 47419100)
38. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, et al. Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2006; 26:1267-1272. (Pubitemid 44305369)